Emerald Health Therapeutics Inc. (TSXV: EMH) has filed a base shelf prospectus (the “Prospectus”) with the securities regulatory authorities in the provinces of British Columbia and Alberta.

The Prospectus, when made final and effective, will enable the company to make offerings of up to $50,000,000 of common shares, preferred shares, debt securities, warrants, units or subscription receipts of the company or a combination thereof from time to time, separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of the offering and as set out in an accompanying prospectus supplement, during the 25-month period that the Prospectus, when made final, remains effective. The specific terms of any future offering will be established in a prospectus supplement to the Prospectus, which supplement will be filed with the applicable Canadian securities regulatory authorities. The net proceeds from any sale of any securities will be used for purposes as set out in the applicable Prospectus supplement.

A copy of the Prospectus can be found under the Company’s profile on sedar.com or may be obtained from the Company upon written request from the contact below.

ON BEHALF OF THE BOARD

Jim Heppell – Lead Director

Emerald Health Therapeutics Inc.

Emerald Health Therapeutics Inc. is a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“), authorized to cultivate and sell both dried medical cannabis flower and medical cannabis oils in Canada. Emerald currently operates out of an indoor facility in Victoria, British Columbia, with plans for a purpose built hybrid greenhouse expansion on 32 acres in metro Vancouver. Emerald prides itself on being one of Canada’s most medically focused producers with one of the industry’s most qualified management teams with regard to pharmaceutical drug discovery, development and distribution. We aim to capture unique niches of both the medical and future recreational cannabis markets through proprietary strains, defensible intellectual property, and superb client and consumer experience.

 

Footnote(s)